Poor Outcome With Front-Line Autologous Transplantation in t(4;14) Multiple Myeloma: Low Complete Remission Rate and Short Duration of Remission
Journal of Clinical OncologyPublished 19 January 2006Open access
Michèle Cavo, Carolina Terragna, Matteo Renzulli, Elena Zamagni, Patrizia Tosi, Nicoletta Testoni
Citations35
SJR quartileQ1
SJR score11.21
SNIP5.98
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
Abstract
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission.
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
New England Journal of MedicineHigh-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
1,765 Citations2003J. A. Child, Gareth J. Morgan +7 more
High-dose therapy with autologous stem-cell rescue is an effective first-line treatment for patients with multiple myeloma who are younger than 65 years of age and trend toward a greater survival benefit in the group of patients with a poor prognosis.
New England Journal of MedicineSingle versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
973 Citations2003Michel Attal, Jean Roy +12 more
As compared with a single autologous stem-cell transplantation after high-dose chemotherapy, double transplantation improves overall survival among patients with myeloma, especially those who do not have a very good partial response after undergoing one transplantation.
New England Journal of MedicineSingle versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
817 Citations2004
BloodClinical and biologic implications of recurrent genomic aberrations in myeloma
661 Citations2003Rafaël Fonseca, Emily Blood +10 more
A stratification of patients into 3 distinct categories allowed for prognostication: poor prognosis group (t(4;14)(p16;q32), t(14; 16)(q32;q23), and - 17p13), intermediate prognosis (- 13q14), and good prognosis groups (all others).
BloodIn multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression
384 Citations2003Jonathan J. Keats, Tony Reiman +6 more
A significant clinical impact is found of the t(4;14) translocation in multiple myeloma that is independent of FGFR3 expression and also predictive of poor response to first-line chemotherapy.
BloodOncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation
357 Citations2002Hervé Avet‐Loiseau, Thierry Façon +6 more
For the first time, this study gives genetic support to the heterogeneity observed in patients with MM and demonstrates that the 14q32 and 13q chromosomal abnormalities are not randomly distributed.
BloodClinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy
356 Citations2005Morie A. Gertz
For high-dose therapy patients, -17(p13) and t(4;14) have clinical importance for estimating time to progression and overall survival and the presence of t( 4; 14) identifies a subset of patients whose time to progress is only 8.2 months.
BloodResults of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities
319 Citations2000Raman Desikan, Bart Barlogie +17 more
BloodRecurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy
318 Citations2002Philippe Moreau, Thierry Façon +6 more
Interest is emphasized in analyzing these two translocations by fluorescence in situ hybridization in prospective therapeutic trials in order to consider these translocations as distinct entities corresponding to a specific oncogenesis and prognosis.
BloodCyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation
120 Citations2003Simona Soverini, Michèle Cavo +18 more
It is concluded that cyclin D1 overexpression is closely associated with 11q abnormalities and identifies a subset of MM patients who are more likely to have prolonged duration of remission and EFS following autologous transplantation.
Journal of Clinical OncologyClinical Outcomes in t(4;14) Multiple Myeloma: A Chemotherapy-Sensitive Disease Characterized by Rapid Relapse and Alkylating Agent Resistance
97 Citations2005Wilfrid Jaksic, Suzanne Trudel +7 more
It is concluded that t(4;14)-positive multiple myeloma is chemotherapy sensitive but rapid relapse occurs, and resistance to alkylating agents is evident at relapse.
BloodSuperiority of Double over Single Autologous Stem Cell Transplantation as First-Line Therapy for Multiple Myeloma.
27 Citations2004Michèle Cavo, Claudia Cellini +9 more
In comparison with a single autologous transplantation, double transplantation significantly prolonged EFS and TTP among younger (< 60 years) patients with previously untreated MM and was of particular benefit for patients who failed at least nCR.
BloodDirect Adoptive Transfer of Cytomegalovirus-Specific CTL from Unrelated Donors to Stem Cell Transplant Patients Following Selection by HLA-Peptide Tetramers.
6 Citations2004Mark Cobbold, Persis Amrolia +9 more
Data from six patients undergoing stem cell transplantation from HLA identical sibling donors are consistent with the hypothesis that antigen-specific CMV specific CTL can be safely infused to recipients of VUD SCT and expand directly in vivo.